الفهرس 
A clinicoepidemiological retrospective study of cases of uterine sarcoma who presented to radiotherapy department in NCI Cairo university in the period from jan 2000-Dec 2012
AbstractOnly 14 pages are availabe for public view
 |  | from | 176 |  |  |
| | | from | 176 | | |
Abstract
Uterine sarcomas are rare tumors that account for approximately 1% of female genital tract malignancies and 3% to 7% of uterine cancers. To study the prevalence, stage and treatment results of uterine sarcoma in cases presented to national cancer institute-Cairo university during the period from 2000 to 2012 and to propose the recommendations for the value of combined modality therapy as standard of care for our patients. Retrospective study of 85 patients presented to national cancer institute from January 2000 to December 2012 with uterine sarcoma who underwent surgery then received Radiation therapy with or without brachytherapy or Radiation therapy with chemotherapy including radiation therapy details, type of chemotherapy, overall treatment period, and site of primary disease. Patients with metastatic disease, or no pathological confirmation were excluded The most frequently encountered pathology was malignant mixed mullarian tumour accounting for 40%. Patients most frequently presented with stage III disease. The most dominant site of metastasis on follow up was lung. The most frequently used treatment modality was surgery in combination with RT (52.9%), while 41.2% of the studied patients underwent surgery alone, 25.9 % recieved Brachytherapy after EBRT and 5.9% of patients underwent surgery followed by EBRT and chemotherapy. Of the evaluated patients, 70.3% achieved complete remission (no local recurrence). Addition of RT to surgery in treatment of patients with uterine sarcoma improved Local control, overall and disease-free survival with a highly statistically significant differences P value<0.001